Dr. Abdullah Kutlar, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 55
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 128
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
GA license 034751
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Wellstar Mcg Health, Affiliated With Med Col Augusta, GA
- Phoebe Putney Memorial Hospital Albany, GA
- Phoebe Worth Medical Center Sylvester, GA
Medical groups
- Wellstar Medical Group LLC (3,093 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 128
- Services billed
- 261
- Patients’ average age
- 61
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 213 | 109 |
| Established patient office or other outpatient visit, 20-29 minutes | 52 | 35 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 44 | 22 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 36 | 20 |
| Hospital discharge day management, 30 minutes or less | 15 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Oxycodone Hcl Other prescribers in Augusta, GA | 241 |
| Morphine Sulfate Er (morphine sulfate) Other prescribers in Augusta, GA | 196 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in Augusta, GA | 184 |
| Hydroxyurea Other prescribers in Augusta, GA | 88 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Augusta, GA | 86 |
| Eliquis (apixaban) Other prescribers in Augusta, GA | 37 |
| Ibuprofen Other prescribers in Augusta, GA | 36 |
| Gabapentin Other prescribers in Augusta, GA | 32 |
| Promethazine Hcl Other prescribers in Augusta, GA | 30 |
| Hydromorphone Hcl Other prescribers in Augusta, GA | 29 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 17 payments worth $28,231 in total to this clinician.
| Genzyme Corporation | $13,767 |
|---|---|
| Vertex Pharmaceuticals Incorporated | $10,000 |
| Genetix Biotherapeutics Inc | $3,400 |
| Agios Pharmaceuticals, Inc. | $1,001 |
| Novo Nordisk Inc | $48.12 |
| Pharmacosmos Therapeutics Inc. | $15.20 |
| Consulting Fee | $27,016 |
|---|---|
| Travel and Lodging | $814 |
| Food and Beverage | $401 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation May 16, 2025 | Consulting Fee QFITLIA | $12,615 |
| Vertex Pharmaceuticals Incorporated Dec 11, 2025 | Consulting Fee | $4,250 |
| Genetix Biotherapeutics Inc Sep 14, 2025 | Consulting Fee Lyfgenia · Gene Therapy | $2,380 |
| Vertex Pharmaceuticals Incorporated Mar 19, 2025 | Consulting Fee | $1,500 |
| Vertex Pharmaceuticals Incorporated Mar 19, 2025 | Consulting Fee | $1,250 |
| Vertex Pharmaceuticals Incorporated Nov 7, 2025 | Consulting Fee | $1,250 |
| Genetix Biotherapeutics Inc Jul 8, 2025 | Consulting Fee Skysona · Gene Therapy | $1,020 |
| Agios Pharmaceuticals, Inc. Oct 15, 2025 | Consulting Fee PYRUKYND · Genetically Defined Disease | $1,001 |
| Vertex Pharmaceuticals Incorporated Mar 19, 2025 | Consulting Fee | $1,000 |
| Vertex Pharmaceuticals Incorporated Mar 19, 2025 | Consulting Fee | $750 |
All 12 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Vertex Pharmaceuticals Incorporated Dec 11, 2025 | Consulting Fee | $4,250 |
| Vertex Pharmaceuticals Incorporated Nov 7, 2025 | Consulting Fee | $1,250 |
| Agios Pharmaceuticals, Inc. Oct 15, 2025 | Consulting Fee PYRUKYND · Genetically Defined Disease | $1,001 |
| Genetix Biotherapeutics Inc Sep 14, 2025 | Consulting Fee Lyfgenia · Gene Therapy | $2,380 |
| Genetix Biotherapeutics Inc Jul 8, 2025 | Consulting Fee Skysona · Gene Therapy | $1,020 |
| Genzyme Corporation May 16, 2025 | Consulting Fee QFITLIA | $12,615 |
| Genzyme Corporation May 16, 2025 | Travel and Lodging QFITLIA · travel to Cambridge, MA · in-kind | $501 |
| Genzyme Corporation May 16, 2025 | Travel and Lodging QFITLIA · travel to Cambridge, MA · in-kind | $313 |
| Vertex Pharmaceuticals Incorporated Mar 19, 2025 | Consulting Fee | $1,500 |
| Vertex Pharmaceuticals Incorporated Mar 19, 2025 | Consulting Fee | $1,250 |
| Vertex Pharmaceuticals Incorporated Mar 19, 2025 | Consulting Fee | $1,000 |
| Vertex Pharmaceuticals Incorporated Mar 19, 2025 | Consulting Fee | $750 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 3 companies. The companies reported $550,369 in research payments for these studies, mostly to the institutions running them.
- An Open Label, Multicenter Roll-over Extension Program (REP) to Characterize the Long-term Safety and Tolerability of Iptacopan (LNP023) in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Completed PN…
Novartis Pharmaceuticals Corporation - An Open-label, Multi-center, Phase IV, Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
Novartis Pharmaceuticals Corporation - A Phase III, Multicenter, Randomized, Placebo Controlled, Double-blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) Versus Placebo, With or Without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent…
Novartis Pharmaceuticals Corporation - A Multicenter, Single Arm, Open-label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily Iptacopan in Adult PNH Patients Who Have Hb10 g/dL in Response to Anti-C5 Antibody and Switch to Iptacopan
Novartis Pharmaceuticals Corporation - Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry
Alexion Pharmaceuticals, Inc. - 4202-HEM-301
Novo Nordisk As
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.